emtricitabine + tenofovir alafenamide fumarate · Medicine question

Which HIV-1 mutation is a reason to avoid Emtricitabine/Tenofovir Alafenamide Gilead in patients previously treated with antiretrovirals?

Name: Which HIV-1 mutation is a reason to avoid Emtricitabine/Tenofovir Alafenamide Gilead in patients previously treated with antiretrovirals?
Published: 2026-11-08T01:47:23.003Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Emtricitabine/Tenofovir Alafenamide Gilead should be avoided in patients previously treated with antiretrovirals whose HIV-1 harbours the K65R mutation.

Sources for this answer

Emtricitabine/Tenofovir Alafenamide Gilead 200 mg/10 mg film coated tabletsGilead Sciences Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 25Document updated 22 October 2025

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about emtricitabine + tenofovir alafenamide fumarate